The role of color doppler flow in the management of nonmetastatic gestational trophoblastic disease

Ron Tepper, Adrian Shulman, Marco Altaras, Shmul Goldberger, Ron Maymon, Michael Holzinger, Yoram Beyth

Research output: Contribution to journalArticlepeer-review

Abstract

Three patients with findings suggestive of invasive gestational trophoblastic neoplasm and lung metastasis were assessed by color Doppler transvaginal ultrasound, before and during chemotherapy. The sonographic findings were correlated with β-hCG levels measured at various stages of treatment. Results were compared with blood flow indices found during normal first trimester pregnancies, and those following elective termination of pregnancy. The mean resistance indices were significantly lower in the patients treated with chemotherapy (0.410 ± 0.04) than in the early pregnancy control group (5-8 weeks gestation; n = 20, resistance index = 0.494 ± 0.06). The difference between the groups was statistically significant (x2; P < 0.05). No pathological flow patterns could be discerned in 10 patients, who after termination of pregnancy had β-hCG levels below 5 IU/ml. The response of gestational trophoblastic neoplasms to chemotherapy could be reliably assessed by observing the changes in flow resistance, which paralleled the gradual decrements in serial measure-ments of β-hCG levels. Thus, the statistically significant results of our study are very encouraging and may indicate that color Doppler flow is a noninvasive, reproducible, useful and highly reliable new diagnostic approach for the diagnosis and management of patients suffering from uterine malignant gestational trophoblastic disease.

Original languageEnglish
Pages (from-to)14-17
Number of pages4
JournalGynecologic and Obstetric Investigation
Volume38
Issue number1
DOIs
StatePublished - 1994
Externally publishedYes

Keywords

  • Chemotherapy
  • Doppler flow
  • Malignant gestational trophoblastic disease

Fingerprint

Dive into the research topics of 'The role of color doppler flow in the management of nonmetastatic gestational trophoblastic disease'. Together they form a unique fingerprint.

Cite this